Organization (Other)
PIERRE FABRE MEDICAMENT
ClinicalTrials.gov lists PIERRE FABRE MEDICAMENT as lead sponsor of 73 trials. It has 38 active development programs and 22 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers PIERRE FABRE MEDICAMENT: 73 lead-sponsored trials and 1 legal-entity registration. Part of PIERRE FABRE SA.
Disease areas (54)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Melanoma | 10 |
| Lung Neoplasms | 9 |
| Breast Neoplasms | 8 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Colorectal Neoplasms | 5 |
Showing 5 of 54 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 6 |
| 2023 | 4 |
| 2022 | 12 |
| 2021 | 8 |
| 2020 | 2 |
| 2019 | 3 |
| 2017 | 3 |
| 2016 | 3 |
| 2015 | 4 |
| 2014 | 7 |
Showing 10 of 18 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 60 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (38)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Encorafenib and Binimetinib | Melanoma | Phase 3 | 1 |
| "Capecitabine" | Breast Neoplasms | Phase 3 | 3 |
| Binimetinib | Lung Neoplasms | Phase 2 | 1 |
| Binimetinib | Carcinoma, Non-Small-Cell Lung | Phase 2 | 1 |
| Encorafenib | Carcinoma, Non-Small-Cell Lung | Phase 2 | 1 |
Showing 5 of 38 active programs.
Approved assets (22)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Permixon® 160 mg | 2 |
| Tamsulosine Arrow LP | 1 |
| DEXERYL | 1 |
| 5-fluorouracil 4% (Tolak) | 1 |
| DC071 | 1 |
Showing 5 of 22 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 44% hit target (n=16) | 65% on time (n=17) |
Journals published in (51)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood | 5 |
| Lung cancer (Amsterdam, Netherlands) | 5 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 4 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 4 |
| Bone marrow transplantation | 3 |
Showing 5 of 51 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 264 | 14 | 2025-11-18 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 4 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Pierre Fabre Medicament | Gaillac, FR | EMA, FDA, Health Canada | |
| Pierre Fabre Medicament | Ussel, FR | EMA |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Iqvia Holdings Inc. | Uses vendor | 2 |
| Ellye | Co sponsors trial with | 1 |
| Fondation du LEEM | Co sponsors trial with | 1 |
| Nutricia Nutrition Clinique | Co sponsors trial with | 1 |
| University Hospital, Brest | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (355)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-05-27 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-01-28 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-11-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-10-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 355 events.
Biomarker capability evidence (205)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial collaborator | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 205 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.